Context Therapeutics (CNTX) Total Current Liabilities (2020 - 2026)
Context Therapeutics (CNTX) posted Total Current Liabilities of $6.5 million for Q1 2026, down 18.52% sequentially from $8.0 million in Q4 2025, and up 243.88% YoY from $1.9 million in Q1 2025.
Context Therapeutics (CNTX) Total Current Liabilities (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $6.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 243.88% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (up 243.88% YoY) and the FY2025 annual result came in at $8.0 million, up 191.8% from the prior year.
- Total Current Liabilities fell to $6.5 million in Q1 2026 per CNTX's latest filing, from $8.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $8.0 million in Q4 2025 and troughed at $1.6 million in Q2 2024.
- A 5-year average of $3.8 million and a median of $3.2 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2026: Total Current Liabilities plunged 57.3% in 2024, then surged 243.88% in 2026.
- Over 5 years, Total Current Liabilities stood at $3.2 million in 2022, then soared by 30.68% to $4.2 million in 2023, then tumbled by 34.43% to $2.7 million in 2024, then jumped by 191.8% to $8.0 million in 2025, then slipped by 18.52% to $6.5 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $6.5 million, $8.0 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Context Therapeutics | 49.23 Mn | 49.23 Mn | - | 7.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.88 Mn |
| Mar 31, 2026 | 6.53 Mn |
| Dec 31, 2025 | 8.02 Mn |
| Sep 30, 2025 | 6.04 Mn |
| Jun 30, 2025 | 4.56 Mn |
| Mar 31, 2025 | 1.90 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | 2.33 Mn |
| Jun 30, 2024 | 1.60 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 4.19 Mn |
| Sep 30, 2023 | 4.60 Mn |
| Jun 30, 2023 | 3.76 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 3.21 Mn |
| Sep 30, 2022 | 4.01 Mn |
| Jun 30, 2022 | 3.04 Mn |
| Mar 31, 2022 | 1.61 Mn |
| Dec 31, 2021 | 3.03 Mn |
| Sep 30, 2021 | 4.41 Mn |